• ArcherDX, Inc., a Boulder, Colo. - based company focused on NGS -
based gene fusion detection assays, raised $ 35 million in Series A preferred funding.
Not exact matches
The
fusion of these two
genes was observed in just three percent of tumors studied, so any therapy
based on this particular genetic aberration would apply to only a small subset of glioblastoma patients.
This application uses calculated break points to determine
fusion genes based on the latest annotation for genomic sequence information, and where relevant the structural variation (SV) events are annotated with predicted RNA and protein sequences.